Jupiter Neurosciences, Inc. (JUNS): Total Liabilities
$7.40M
As of 2025-12-31
$4.08M
As of 2026-06-30
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.40M | +264.3% | 2026-04-01, Balance as of period end |
| 2024-12-31 | $2.03M | -65.9% | 2026-04-01, Balance as of period end |
| 2023-12-31 | $5.95M | n/a | 2025-03-28, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Jupiter Neurosciences, Inc. (JUNS) | 2025-12-31 | $7.40M | +264.3% |
| Skinvisible, Inc. (SKVI) | 2025-12-31 | $10.39M | +10.8% |
| Bioadaptives, Inc. (BDPT) | 2025-12-31 | $2.36M | +36.5% |
| PRF Technologies Ltd. (PRFX) | 2025-12-31 | $2.71M | +0.3% |
| Talphera, Inc. (TLPH) | 2025-12-31 | $12.68M | +23.9% |
| Impact Biomedical Inc. (IBO) | 2025-12-31 | $1.85M | -85.8% |
| Lyell Immunopharma, Inc. (LYEL) | 2025-12-31 | $91.85M | -15.0% |
| Neonc Technologies Holdings, Inc. (NTHI) | 2025-12-31 | $20.33M | +127.9% |
| Altimmune, Inc. (ALT) | 2025-12-31 | $55.04M | +248.4% |
Compare JUNS, SKVI, BDPT, PRFX side by side · Screen every company in Pharmaceutical Preparations ↗